All In Biotech

Drug Trial Radar · NCT01049425

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,198

Actual

Start

Feb 5, 2009

Primary completion

Mar 1, 2017

Study completion May 15, 2018

Sponsor

Lead sponsor
Women's Cancer Study Group GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi; Amgen
First posted
Jan 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The planned trial compares an anthracycline-free taxane based regimen versus a modern third generation (anthracycline/taxane-based) regimen in HER2/neu non-over expressing tumors. The aim is to define a further anthracycline-free standard and to spare anthracycline toxicity to a patient, who will only have a modest benefit from this compound. Prior to randomization for chemotherapy for all patients with HR positive disease OncotypeDX® will be performed to identify patients who should not receive chemotherapy. Secondary objectives of this trial will be to compare overall survival and toxicity between the two chemotherapy arms, to evaluate survival in the observation arm and to perform translational research regarding prognostic and predictive factors.

Conditions

  • Primary Breast Cancer
  • Her2 Non-overexpressing

Interventions

  • EpirubicinDrug

    4 cycles, intravenous use, day 1 every three weeks

  • CyclophosphamideDrug

    4 cycles, intravenous infusion, day 1 every three weeks

  • DocetaxelDrug

    4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy

  • CyclophosphamideDrug

    6 cycles, intravenous infusion, day 1 every 3 weeks

  • DocetaxelDrug

    6 cycles, intravenous infusion, day one every three weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. disease-free survival in patients treated with either 6 cycles of Docetaxel / Cyclophosphamide chemotherapy or 4 cycles of EC followed by 4 cycles of Docetaxel as adjuvant treatmentTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bethesda Krankenhaus

    Mönchengladbach, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.